Impel Pharmaceuticals (NASDAQ:IMPL) reported its Q1 earnings results on Friday, May 12, 2023 at 08:00 AM.
Here’s what investors need to know about the announcement.
Earnings
Impel Pharmaceuticals missed estimated earnings by 41.11%, reporting an EPS of $-1.27 versus an estimate of $-0.9.
Revenue was up $2.61 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.14 which was followed by a 3.82% increase in the share price the next day.
Here’s a look at Impel Pharmaceuticals’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -1.11 | -1 | -1.05 | -1.05 |
| EPS Actual | -0.97 | -1.31 | -1.09 | -1.17 |
| Revenue Estimate | 4.97M | 5.82M | 3.83M | 1.80M |
| Revenue Actual | 5.01M | 3.08M | 2.80M | 1.76M |
To track all earnings releases for Impel Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
